PROFESSIONAL EDITION

The largest community of pharma leaders

Eureka Therapeutics Announces Successful Preclinical Results of InvisiMask™ Human Antibody Nasal Spray Against SARS-CoV-2 Infection

EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc. announced today successful preclinical results from its InvisiMask™ Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours. InvisiMask is an intra-nasal application of a proprietary human monoclonal antibody that is intended to be used as a prophylactic against contracting SARS-CoV-2 infection. Results of the study, which has not been peer reviewed, are availab

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles